Survivorship and MDT working in gynaecological oncology

She finished her chemoradiotherapy for stage IIB cervical cancer nine months ago, her scans are clear, and the cancer is gone — but she is back in your clinic in tears, not with bleeding, but with painful intercourse that has shut down her relationship, a leg that aches and swells, hot flushes that wreck her sleep, and a conviction that every twinge is the cancer returning. Cure was the operation; survivorship is the appointment in front of you. If your survivorship visit stops at "vault smear and CA-125 normal, see you in six months," you have missed the entire disease.^[5][11]

Survivorship defined — and why it is its own topic

A cancer survivor is defined from the moment of diagnosis through the balance of life, and survivorship care is organised across three phases: the acute phase (diagnosis to completion of primary treatment), the extended phase (surveillance and recovery), and permanent long-term survival. For gynaecological oncology this is no longer a fringe concern — rising endometrial cancer incidence, high cervical and ovarian survival, and the durable toxicity of pelvic radiotherapy mean most of your patients will spend far more of their lives as survivors than as patients on treatment.^[1][2]

The defining insight of modern survivorship care is that surveillance and survivorship are not the same thing. Surveillance is the hunt for recurrence. Survivorship is the whole-of-life management of the consequences of disease and treatment. A clinic that does only the first delivers a woman with a clear scan and a ruined life. The survivorship care plan is the instrument that forces both into one document.^[1][4]

^{[1] [10] [11]}

References20ShowHide

1. [1]Mayer DK, Nekhlyudov L, Snyder CF, et al. American Society of Clinical Oncology clinical expert statement on cancer survivorship care planning J Oncol Pract, 2014.PMID 25316025
2. [2]Mayer DK, Shapiro CL, Jacobson P, et al. Assuring Quality Cancer Survivorship Care: We've Only Just Begun Am Soc Clin Oncol Educ Book, 2015.PMID 25993226
3. [3]Chan RJ, McErlean G, Crawford-Williams F, et al. Joint Cancer Nurses Society of Australia-Clinical Oncology Society of Australia Position Statement on the Contribution of Nurses to Cancer Survivorship Care in Australia Asia Pac J Clin Oncol, 2026.PMID 42383647
4. [4]Grant M, Economou D, Ferrell B, et al. Educating health care professionals to provide institutional changes in cancer survivorship care J Cancer Educ, 2012.PMID 22271583
5. [5]Woopen H, Zwimpfer T, Brenner L, et al. Patients' Perception of Follow-Up Care and Personal Health Status of 677 Long-Term Survivors of Gynecological Cancer from the Study "Expression IX-Long-Term Survival with Gynecological Cancer": The International NOGGO, ENGOT and GCIG Survey Cancers (Basel), 2026.PMID 42193006
6. [6]Jeppesen MM, Jensen PT, Hansen DG, et al. Patient-initiated follow up affects fear of recurrence and healthcare use: a randomised trial in early-stage endometrial cancer BJOG, 2018.PMID 29978593
7. [7]Holtzman S, Gellman C, Chess I, et al. Surveillance Visits for Ovarian Cancer: Is It Time to Reconsider? J Surg Oncol, 2025.PMID 40990395
8. [8]Hamilton CA, Pothuri B, Arend RC, et al. Endometrial cancer: A society of gynecologic oncology evidence-based review and recommendations, part II Gynecol Oncol, 2021.PMID 33451724
9. [9]Barretina-Ginesta MP, Madariaga A, Gil-Martín M, et al. Addressing unmet needs in long-term survivors of ovarian cancer (ENGOT ov40/NOGGO S13/GEICO 71-R/Expression VI): insights from a Spanish cohort Int J Gynecol Cancer, 2026.PMID 41951282
10. [10]Hathout L, Zhang Y, Lymberis S, et al. A Systematic Review of Patient-Reported Outcomes on the Impact of Radiation Therapy on Sexual Health in Patients With Gynecologic Cancer Int J Radiat Oncol Biol Phys, 2026.PMID 41720168
11. [11]Naert E, Decruyenaere A, Bultijnck R, et al. Vaginal morbidity, sexual functioning, and health-related quality of life in cervical cancer survivors: a cross-sectional multicenter study (VAMOS) Support Care Cancer, 2023.PMID 37975947
12. [12]Martins J, Vaz AF, Grion RC, et al. Topical estrogen, testosterone, and vaginal dilator in the prevention of vaginal stenosis after radiotherapy in women with cervical cancer: a randomized clinical trial BMC Cancer, 2021.PMID 34112100
13. [13]Law E, Kelvin JF, Thom B, et al. Prospective study of vaginal dilator use adherence and efficacy following radiotherapy Radiother Oncol, 2015.PMID 26164775
14. [14]Charatsi D, Vanakara P, Evaggelopoulou E, et al. Vaginal dilator use to promote sexual wellbeing after radiotherapy in gynecological cancer survivors Medicine (Baltimore), 2022.PMID 35089231
15. [15]Brotto LA, Yule M, Breckon E Psychological interventions for the sexual sequelae of cancer: a review of the literature J Cancer Surviv, 2010.PMID 20602188
16. [16]Robijns J, Censabella S, Bollen H, et al. Vaginal mucositis in patients with gynaecological cancer undergoing (chemo-)radiotherapy: a retrospective analysis J Obstet Gynaecol, 2022.PMID 35170399
17. [17]Kurtuluş D, Arkan K, Suçeken FY, et al. Pelvic Floor Dysfunction Following Gynecologic Cancer Surgery and Adjuvant Therapy: Epidemiology, Mechanisms, and Management-A Systematic Review Int Urogynecol J, 2026.PMID 41579191
18. [18]Akizuki N, Yamawaki S, Akechi T, et al. Development of an Impact Thermometer for use in combination with the Distress Thermometer as a brief screening tool for adjustment disorders and/or major depression in cancer patients J Pain Symptom Manage, 2005.PMID 15652442
19. [19]Sessa C, Travado L, Calaminus G, et al. European Cancer Organisation Essential Requirements for Quality Cancer Care for ovarian cancer: Focus on the multidisciplinary team Tumori, 2025.PMID 39643948
20. [20]Soukup T, Hamad W, Quinney E, et al. Operationalising MDT streamlining through standards of care: a framework for specification and implementation Front Health Serv, 2026.PMID 42318165